Metastatic carcinoma of unknown primary: Diagnostic approach using immunohistochemistry

Advances in Anatomic Pathology

Volumn 22, Issue 3, 2015, Pages 149-167

  Conner, James R ^a   Hornick, Jason L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

carcinoma of unknown primary; immunohistochemistry; metastasis; transcription factors; tumor biomarkers

Indexed keywords

ANTIBODY; CYTOPLASM PROTEIN; ESTROGEN RECEPTOR; KERATIN; PROGESTERONE RECEPTOR; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NKX3-1; TRANSCRIPTION FACTOR PAX8; TRANSCRIPTION FACTOR SATB2; TRANSCRIPTION FACTOR SF1; UNCLASSIFIED DRUG; WT1 PROTEIN; TUMOR MARKER;

BIOPSY; CANCER OF UNKNOWN PRIMARY SITE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; METABOLISM; NEOPLASMS, UNKNOWN PRIMARY;

HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; NEOPLASMS, UNKNOWN PRIMARY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84928492534     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000069     Document Type: Review

References (187)

1. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379:1428-1435.
2. Loffler H, Puthenparambil J, Hielscher T, et al. Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma. Dtsch Arztebl Int. 2014;111:481-487.
3. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43:2026-2036.
4. Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 2011;8:701-710.
5. Gabbiani G, Kapanci Y, Barazzone P, et al. Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol. 1981;104:206-216.
6. Schlegel R, Banks-Schlegel S, McLeod JA, et al. Immunoperoxidase localization of keratin in human neoplasms: a preliminary survey. Am J Pathol. 1980;101:41-49.
7. Miettinen M, Lehto VP, Badley RA, et al. Expression of intermediate filaments in soft-tissue sarcomas. Int J Cancer. 1982;30:541-546.
8. Schweizer J, Bowden PE, Coulombe PA, et al. New consensus nomenclature for mammalian keratins. J Cell Biol. 2006;174:169-174.
9. Hsu JD, Yao CC, Han LW, et al. CAM5.2 is not identical to cytokeratins 8 and 18. Am J Clin Pathol. 2010;133:514.
10. Ordonez NG. Broad-spectrum immunohistochemical epithelial markers: a review. Hum Pathol. 2013;44: 1195-1215.
11. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
12. Sasaki E, Tsunoda N, Hatanaka Y, et al. Breast-specific expression of mgb1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. Mod Pathol. 2007;20: 208-214.
13. Lotan TL, Ye H, Melamed J, et al. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009;33:1037-1041.
14. Raju U, Ma CK, Shaw A. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study. Mod Pathol. 1993;6:516-520.
15. Yamasaki H, Saw D, Zdanowitz J, et al. Ovarian carcinoma metastasis to the breast case report and review of the literature. Am J Surg Pathol. 1993;17:193-197.
16. Reyes C, Gomez-Fernandez C, Nadji M. Metaplastic and medullary mammary carcinomas do not express mammaglobin. Am J Clin Pathol. 2012;137:747-752.
17. Lewis GH, Subhawong AP, Nassar H, et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. Am J Clin Pathol. 2011;135:587-591.
18. Huo L, Zhang J, Gilcrease MZ, et al. Gross cystic disease fluid protein-15 and mammaglobin a expression determined by immunohistochemistry is of limited utility in triplenegative breast cancer. Histopathology. 2013;62:267-274.
19. Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010;23:654-661.
20. Striebel JM, Dacic S, Yousem SA. Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. Am J Surg Pathol. 2008;32:426-432.
21. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41:20-25.
22. Stoll LM, Johnson MW, Gabrielson E, et al. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol. 2010;118:441-449.
23. Mukhopadhyay S, Katzenstein AL. Comparison of monoclonal napsin A, polyclonal napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas. Am J Clin Pathol. 2012;138:703-711.
24. Kim MY, Go H, Koh J, et al. Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin. Histopathology. 2014;65:195-206.
25. Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136:163-171.
26. Yamashita Y, Nagasaka T, Naiki-Ito A, et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol. 2015;28:111-117.
27. Kandalaft PL, Gown AM, Isacson C. The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary. Am J Clin Pathol. 2014;142:830-836.
28. Ballard M, Sangoi A, McKenney JK, et al. Napsin A staining in adrenal cortical neoplasms. Arch Pathol Lab Med. 2013;137:883.
29. Heymann JJ, Hoda RS, Scognamiglio T. Polyclonal napsin A expression: a potential diagnostic pitfall in distinguishing primary from metastatic mucinous tumors in the lung. Arch Pathol Lab Med. 2014;138:1067-1071.
30. Terra SB, Aubry MC, Yi ES, et al. Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma-sensitivity of TTF-1 is superior to napsin. Hum Pathol. 2014;45:294-302.
31. Burt A, Goudie RB. Diagnosis of primary thyroid carcinoma by immunohistological demonstration of thyroglobulin. Histopathology. 1979;3:279-286.
32. Cimino-Mathews A, Sharma R, Netto GJ. Diagnostic use of PAX8, CAIX, TTF-1, and TGB in metastatic renal cell carcinoma of the thyroid. Am J Surg Pathol. 2011;35:757-761.
33. Ordonez NG, El-Naggar AK, Hickey RC, et al. Anaplastic thyroid carcinoma. Immunocytochemical study of 32 cases. Am J Clin Pathol. 1991;96:15-24.
34. Keen CE, Szakacs S, Okon E, et al. CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin. Histopathology. 1999;34:113-117.
35. Tan PH, Cheng L, Rioux-Leclercq N, et al. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013;37:1518-1531.
36. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'renal cell carcinoma marker'. Am J Surg Pathol. 2001;25:1485-1492.
37. Bakshi N, Kunju LP, Giordano T, et al. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic implications. Appl Immunohistochem Mol Morphol. 2007;15:310-315.
38. Ingold B, Wild PJ, Nocito A, et al. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma. Histopathology. 2008;52:674-681.
39. Pan Z, Grizzle W, Hameed O. Significant variation of immunohistochemical marker expression in paired primary and metastatic clear cell renal cell carcinomas. Am J Clin Pathol. 2013;140:410-418.
40. Timek DT, Shi J, Liu H, et al. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012;138:203-210.
41. Minervini MI, Demetris AJ, Lee RG, et al. Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol. 1997; 10:686-692.
42. Kakar S, Gown AM, Goodman ZD, et al. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131:1648-1654.
43. Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817-825.
44. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575.
45. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147-1154.
46. Fujiwara M, Kwok S, Yano H, et al. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol. 2012;120:230-237.
47. Genega EM, Hutchinson B, Reuter VE, et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
48. Stein BS, Vangore S, Petersen RO, et al. Immunoperoxidase localization of prostate-specific antigen. Am J Surg Pathol. 1982;6:553-557.
49. Hameed O, Humphrey PA. Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol. 2005;22:88-104.
50. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255.
51. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006;30:705-712.
52. Varma M, Morgan M, Jasani B, et al. Polyclonal anti-PSA is more sensitive but less specific than monoclonal anti-PSA: implications for diagnostic prostatic pathology. Am J Clin Pathol. 2002;118:202-207.
53. Parwani AV, Marlow C, Demarzo AM, et al. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol. 2006;30:1231-1236.
54. Varma M, Jasani B. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature. Histopathology. 2005;47:1-16.
55. Bodey B, Bodey B Jr, Kaiser HE. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells. Anticancer Res. 1997;17: 2577-2581.
56. Alanen KA, Kuopio T, Collan YU, et al. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. Breast Cancer Res Treat. 1999;56:169-176.
57. Howarth DJ, Aronson IB, Diamandis EP. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer. 1997;75:1646-1651.
58. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol. 2000; 24:579-586.
59. Tazawa K, Kurihara Y, Kamoshida S, et al. Localization of prostate-specific antigen-like immunoreactivity in human salivary gland and salivary gland tumors. Pathol Int. 1999;49:500-505.
60. Robine S, Huet C, Moll R, et al. Can villin be used to identify malignant and undifferentiated normal digestive epithelial cells? Proc Natl Acad Sci U S A. 1985;82:8488-8492.
61. Moll R, Robine S, Dudouet B, et al. Villin: a cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;54:155-169.
62. Bacchi CE, Gown AM. Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffinembedded tissue. Lab Invest. 1991;64:418-424.
63. Lin F, Shi J, Zhu S, et al. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch Pathol Lab Med. 2014;138:1015-1026.
64. Suh N, Yang XJ, TretiakovaMS, et al. Value of CDX2, villin, and alpha-methylacyl coenzyme a racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol. 2005;18:1217-1222.
65. Pelkey TJ, Frierson HF Jr, Mills SE, et al. The alpha subunit of inhibin in adrenal cortical neoplasia. Mod Pathol. 1998;11:516-524.
66. Zhang PJ, Genega EM, Tomaszewski JE, et al. The role of calretinin, inhibin, melan-A, BCL-2, and c-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003;16:591-597.
67. Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009;33:354-366.
68. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12-18.
69. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678-686.
70. Renshaw AA, Granter SR. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol. 1998;11:1160-1164.
71. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113:683-687.
72. Parker DC, Folpe AL, Bell J, et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol. 2003;27:1-10.
73. Hoang LL, Tacha DE, Qi W, et al. A newly developed uroplakin II antibody with increased sensitivity in urothelial carcinoma of the bladder. Arch Pathol Lab Med. 2014;138:943-949.
74. Li W, Liang Y, Deavers MT, et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014;142:864-871.
75. Smith SC, Mohanty SK, Kunju LP, et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology. 2014;65:132-138.
76. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27: 303-310.
77. Moskaluk CA, Zhang H, Powell SM, et al. CDX2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol. 2003;16:913-919.
78. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol. 2004;17:1392-1399.
79. De Lott LB, Morrison C, Suster S, et al. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarraybased study of 629 tumors from various sites. Arch Pathol Lab Med. 2005;129:1100-1105.
80. Park do Y, Srivastava A, Kim GH, et al. CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. Mod Pathol. 2010;23:54-61.
81. Rossi G, Murer B, Cavazza A, et al. Primary mucinous (socalled colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol. 2004;28:442-452.
82. Saad RS, Cho P, Silverman JF, et al. Usefulness of CDX2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol. 2004;122:421-427.
83. O'Connell FP, Wang HH, Odze RD. Utility of immunohistochemistry in distinguishing primary adenocarcinomas from metastatic breast carcinomas in the gastrointestinal tract. Arch Pathol Lab Med. 2005;129:338-347.
84. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005;18:19-25.
85. Vang R, Gown AM, Wu LS, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19:1421-1428.
86. Sullivan LM, Smolkin ME, Frierson HF Jr, et al. Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology. Am J Surg Pathol. 2008;32:1608-1612.
87. Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35: 937-948.
88. Dragomir A, de Wit M, Johansson C, et al. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol. 2014;141:630-638.
89. Wang S, Zhou J, Wang XY, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219:114-122.
90. Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology. 2013;63:36-49.
91. Ordonez NG. Value of GATA3 immunostaining in tumor diagnosis: a review. Adv Anat Pathol. 2013;20:352-360.
92. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
93. Liu H, Shi J, Wilkerson ML, et al. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol. 2012;138:57-64.
94. Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13-22.
95. Clark BZ, Beriwal S, Dabbs DJ, et al. Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas. Am J Clin Pathol. 2014;142:64-71.
96. Betts G, Beckett E, Nonaka D. GATA3 shows differential immunohistochemical expression across thyroid and parathyroid lesions. Histopathology. 2014;65:288-290.
97. Schwartz LE, Begum S, Westra WH, et al. GATA3 immunohistochemical expression in salivary gland neoplasms. Head Neck Pathol. 2013;7:311-315.
98. Chang A, Amin A, Gabrielson E, et al. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung. Am J Surg Pathol. 2012;36:1472-1476.
99. Zhao L, Antic T, Witten D, et al. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Am J Surg Pathol. 2013;37:1876-1881.
100. Liang Y, Heitzman J, Kamat AM, et al. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014;45:1466-1472.
101. Amin MB, Trpkov K, Lopez-Beltran A, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014;38:e20-e34.
102. Ellis CL, Chang AG, Cimino-Mathews A, et al. GATA-3 immunohistochemistry in the differential diagnosis of adenocarcinoma of the urinary bladder. Am J Surg Pathol. 2013;37:1756-1760.
103. Liu H, Shi J, Prichard JW, et al. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. Am J Clin Pathol. 2014;141:648-655.
104. Wendroth SM, Mentrikoski MJ, Wick MR. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin. Ann Diagn Pathol. 2015;19:6-9.
105. Bieberich CJ, Fujita K, He WW, et al. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem. 1996;271:31779-31782.
106. Bowen C, Bubendorf L, Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000;60:6111-6115.
107. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol. 2010;34:1097-1105.
108. Asch-Kendrick RJ, Samols MA, Lilo MT, et al. NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas. J Clin Pathol. 2014;67:768-771.
109. Gordetsky J, Epstein JI. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall. Am J Surg Pathol. 2014;38:941-945.
110. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol. 2011;24:820-828.
111. Nonaka D, Chiriboga L, Soslow RA. Expression of PAX8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566-1571.
112. Siehl JM, Thiel E, Heufelder K, et al. Possible regulation of Wilms' tumour gene 1 (WT1) expression by the paired box genes PAX2 and PAX8 and by the haematopoietic transcription factor GATA-1 in human acute myeloid leukaemias. Br J Haematol. 2003;123:235-242.
113. Nonaka D, Tang Y, Chiriboga L, et al. Diagnostic utility of thyroid transcription factors PAX8 and TTF-2 (FOXE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21:192-200.
114. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218-1227.
115. Weissferdt A, Moran CA. PAX8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am J Surg Pathol. 2011;35:1305-1310.
116. Tong GX, Memeo L, Colarossi C, et al. PAX8 and PAX2 immunostaining facilitates the diagnosis of primary epithelial neoplasms of the male genital tract. Am J Surg Pathol. 2011;35:1473-1483.
117. Ordonez NG. Value of PAX2 immunostaining in tumor diagnosis: a review and update. Adv Anat Pathol. 2012; 19:401-409.
118. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-826.
119. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24:751-764.
120. Woodard AH, Yu J, Dabbs DJ, et al. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin. Am J Clin Pathol. 2011;136:428-435.
121. Toriyama A, Mori T, Sekine S, et al. Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody. Histopathology. 2014;65:465-472.
122. Moretti L, Medeiros LJ, Kunkalla K, et al. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol. 2012;25: 231-236.
123. Carney EM, Banerjee P, Ellis CL, et al. PAX2(-)/PAX8(-)/ inhibin A(+) immunoprofile in hemangioblastoma: a helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system. Am J Surg Pathol. 2011;35:262-267.
124. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-635.
125. Ordonez NG. Value of PAX8, PAX2, napsin a, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. Mod Pathol. 2013;26:1132-1143.
126. Ordonez NG. Value of PAX8, PAX2, claudin-4, and hcaldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2013;26:553-562.
127. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20: 285-314.
128. Sangoi AR, Ohgami RS, Pai RK, et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24:412-424.
129. Long KB, Srivastava A, Hirsch MS, et al. PAX8 expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol. 2010;34:723-729.
130. Koo J, Mertens RB, Mirocha JM, et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin. Mod Pathol. 2012;25:893-901.
131. Civitareale D, Lonigro R, Sinclair AJ, et al. A thyroid-specific nuclear protein essential for tissue-specific expression of the thyroglobulin promoter. EMBO J. 1989;8:2537-2542.
132. Katoh R, Kawaoi A, Miyagi E, et al. Thyroid transcription factor-1 in normal, hyperplastic, and neoplastic follicular thyroid cells examined by immunohistochemistry and nonradioactive in situ hybridization. Mod Pathol. 2000;13: 570-576.
133. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445-452.
134. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol. 2001;25: 363-372.
135. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
136. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
137. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26: 767-773.
138. Jerome Marson V, Mazieres J, Groussard O, et al. Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology. 2004;45:125-134.
139. Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007;131:1561-1567.
140. Strickland-Marmol LB, Khoor A, Livingston SK, et al. Utility of tissue-specific transcription factors thyroid transcription factor 1 and CDX2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med. 2007;131:1686-1690.
141. Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol. 2010;34:1881-1885.
142. Surrey LF, Frank R, Zhang PJ, et al. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels. Am J Surg Pathol. 2014;38:224-227.
143. Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31:1759-1763.
144. Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21:485-490.
145. Bisceglia M, Ragazzi M, Galliani CA, et al. TTF-1 expression in nephroblastoma. Am J Surg Pathol. 2009;33:454-461.
146. An J, Park S, Sung SH, et al. Unusual expression of thyroid transcription factor 1 and napsin A in metastatic adenoid cystic carcinoma of extrapulmonary origin in the lung. Am J Clin Pathol. 2014;141:712-717.
147. Zamecnik J, Chanova M, Kodet R. Expression of thyroid transcription factor 1 in primary brain tumours. J Clin Pathol. 2004;57:1111-1113.
148. Bisceglia M, Galliani C, Rosai J. TTF-1 expression in breast carcinoma-the chosen clone matters. Am J Surg Pathol. 2011;35:1087-1088.
149. Ni YB, Tsang JY, Shao MM, et al. TTF-1 expression in breast carcinoma: an unusual but real phenomenon. Histopathology. 2014;64:504-511.
150. Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol. 2003;27:311-324.
151. Inamura K, Satoh Y, Okumura S, et al. Pulmonary adenocarcinomas with enteric differentiation: Histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas. Am J Surg Pathol. 2005;29:660-665.
152. Bejarano PA, Mousavi F. Incidence and significance of cytoplasmic thyroid transcription factor-1 immunoreactivity. Arch Pathol Lab Med. 2003;127:193-195.
153. Pang Y, von Turkovich M, Wu H, et al. The binding of thyroid transcription factor-1 and hepatocyte paraffin 1 to mitochondrial proteins in hepatocytes: a molecular and immunoelectron microscopic study. Am J Clin Pathol. 2006;125:722-726.
154. Gu K, Shah V, Ma C, et al. Cytoplasmic immunoreactivity of thyroid transcription factor-1 (clone 8G7G3/1) in hepatocytes: true positivity or cross-reaction? Am J Clin Pathol. 2007;128:382-388.
155. Wieczorek TJ, Pinkus JL, Glickman JN, et al. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. Am J Clin Pathol. 2002;118:911-921.
156. Pan CC, Chen PC, Tsay SH, et al. Cytoplasmic immunoreactivity for thyroid transcription factor-1 in hepatocellular carcinoma: a comparative immunohistochemical analysis of four commercial antibodies using a tissue array technique. Am J Clin Pathol. 2004;121:343-349.
157. Lei JY, Bourne PA, diSant'Agnese PA, et al. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs. cholangiocarcinoma and metastatic carcinoma of the liver. Am J Clin Pathol. 2006;125:519-525.
158. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol. 2001;25:815-819.
159. Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001;125:228-231.
160. Ishida M, Sekine S, Fukagawa T, et al. Neuroendocrine carcinoma of the stomach: morphologic and immunohistochemical characteristics and prognosis. Am J Surg Pathol. 2013;37:949-959.
161. Sangoi AR, McKenney JK. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol. 2010;34:423-432.
162. Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161-E171.
163. Duregon E, Volante M, Giorcelli J, et al. Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Hum Pathol. 2013;44:822-828.
164. Gomez-Fernandez C, Daneshbod Y, Nassiri M, et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol. 2008;130:879-882.
165. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
166. Nash JW, Morrison C, Frankel WL. The utility of estrogen receptor and progesterone receptor immunohistochemistry in the distinction of metastatic breast carcinoma from other tumors in the liver. Arch Pathol Lab Med. 2003;127:1591-1595.
167. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
168. Chu PG, Chung L, Weiss LM, et al. Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol. 2011;35:1830-1836.
169. Vang R, Gown AM, Barry TS, et al. Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol. 2006;19:97-105.
170. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006;15:R196-R201.
171. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003;27:1031-1051.
172. Barnoud R, Sabourin JC, Pasquier D, et al. Immunohistochemical expression of WT1 by desmoplastic small round cell tumor: a comparative study with other small round cell tumors. Am J Surg Pathol. 2000;24:830-836.
173. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol. 2000;19:158-163.
174. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol. 2002;117:541-545.
175. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23:110-118.
176. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115.
177. Heatley MK. WT-1 in ovarian and endometrioid serous carcinoma: a meta-analysis. Histopathology. 2005;46:468.
178. Nofech-Mozes S, Khalifa MA, Ismiil N, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol. 2008;21:1147-1155.
179. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804-814.
180. Owens SR, Greenson JK. Immunohistochemical staining for p63 is useful in the diagnosis of anal squamous cell carcinomas. Am J Surg Pathol. 2007;31:285-290.
181. Di Como CJ, Urist MJ, Babayan I, et al. P63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494-501.
182. Mahalingam M, Nguyen LP, Richards JE, et al. The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol. 2010;23:713-719.
183. Ivan D, Hafeez Diwan A, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol. 2005;18:137-142.
184. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34:1805-1811.
185. Mukhopadhyay S, Katzenstein AL. Subclassification of nonsmall cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.
186. Sholl LA, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2010;18:55-61.
187. Bishop JA, Teruya-Feldstein J, Westra WH, et al. P40 (DNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25: 405-415.